Short-course RT increases complete response when added to immunochemotherapy in pMMR rectal cancer
In randomized TORCH-iTNT, adding 25 Gy in 5 fractions before CAPOX plus toripalimab increased complete response from 37.1% to 61.5% in pMMR locally advanced rectal cancer. Long-term outcomes remain pending.